InvestorsHub Logo
Followers 0
Posts 1442
Boards Moderated 0
Alias Born 10/04/2017

Re: StockBro75 post# 5483

Monday, 12/18/2017 5:55:15 PM

Monday, December 18, 2017 5:55:15 PM

Post# of 12427
And EndoPAT can't even compete on terms of cost point, convenience, even accuracy. LXGTF HeartSentry will dominate from the beginning of its clearance by FDA